TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03578237

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cryoneurolysis procedure
Description: Mastectomy (subjects 1-18): Myoscience Iovera device: simulated full cryo cycle without administering gas to the probe.~Mastectomy (subjects 19-end) and all other procedures: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with a SHAM probe that does not deliver gas to the tip or result in a drop in temperature
Study: NCT03102216

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iSTAT
Description: iSTAT troponin, INR, CG4+ and Chem8

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iSTAT
Description: iSTAT troponin, INR, CG4+ and Chem8

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iSTAT
Description: iSTAT troponin, INR, CG4+ and Chem8

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CBC
Description: Complete Blood Count

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CBC
Description: Complete Blood Count

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CBC
Description: Complete Blood Count

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CBC
Description: Complete Blood Count

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: ElectroCardioGram

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: ElectroCardioGram

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: ElectroCardioGram

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: ElectroCardioGram

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: ElectroCardioGram

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: ElectroCardioGram

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lodox
Description: Low dose x-ray

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lodox
Description: Low dose x-ray
Study: NCT02410356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-1106
Description: The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
Study: NCT03102216

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lodox
Description: Low dose x-ray
Study: NCT03423121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic Acid
Description: Participants will be given 1 gram of Tauroursodeoxycholic acid twice daily in the form of four 250mg capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Participants will be given four capsules of the placebo twice daily.
Study: NCT00272220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified directly observed therapy (mDOT)
Description: Peers individually administered the 6-week mDOT intervention at the Beira Day Clinic to mDOT participants during their morning weekday dose. Evening and weekend doses were not observed. Nighttime and weekend doses were self-administered. As part of the daily interaction with participants, peers provided social support, information about the benefits and side effects of HAART, how to address stigma's effect on adherence, and encouragement to participate in community support groups. The peers also provided an important link between the individual and other members of the HIV clinic team and the community.
Study: NCT02673944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peritron+
Description: Peritron+ will be connected to a standard urodynamic analyzer system to measure vesical pressure
Study: NCT03102216

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lodox
Description: Low dose x-ray

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lodox
Description: Low dose x-ray

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lodox
Description: Low dose x-ray
Study: NCT00684125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blake Drains (Blake drain, Ethicon USA)
Description: 19F Blake drain located in the posterior pericardial cavity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard mediastinal drainage
Description: Mediastinal drainage will be accomplished using 28F or 32F chest tube located in the anterior mediastinum
Study: NCT01511107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Clavulanate, 10 days
Description: Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-10

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin-Clavulanate, 5 days
Description: Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-5~Plus~Placebo Days 6-10
Study: NCT03407508

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Comparison of Diets
Description: Okinawan-based Nordic Diet and Control Diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Comparison of Diets
Description: Okinawan-based Nordic Diet and Control Diet
Study: NCT02616016

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI Guided High Intensity Focused Ultrasound
Description: Target treatment of bone metastases using High Intensity Focused Ultrasound
Study: NCT04003337

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Morpho-kinetics selection with time-lapse (Embryoscope) evaluation
Description: Embryos in group B will be selected in blastocyst stage according to morpho-kinetics criteria before the embryo transfer
Study: NCT01241396

Intervention type: OTHER
Intervention: Any MMY treatment
Description: Any line of treatment for MMY
Study: NCT01044420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRI
Description: mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
Study: NCT03001583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program with cooking lessons
Description: Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education program WITHOUT cooking lessons
Description: Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
Study: NCT02480894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc
Study: NCT01767519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOTOX®
Description: BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BOTOX®
Description: BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX®
Description: BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin
Description: Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botox placebo (normal saline)
Description: Botox placebo (normal saline) intradetrusor injection at Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox placebo (normal saline)
Description: Botox placebo (normal saline) intradetrusor injection at Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin placebo
Description: Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: solifenacin placebo
Description: Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
Study: NCT02410356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dGH
Description: The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
Study: NCT01997229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01832207

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo transcutaneous electrical nerve stimulation
Study: NCT02139371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of 64Cu-DOTA-AE105
Description: One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection
Study: NCT03457649

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ARGX-113
Study: NCT03313414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir Treatment for 14 days
Description: 14 day therapy with Sofosbuvir/Velpatasvir
Study: NCT01192126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb new daily disposable
Description: Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Johnson & Johnson Acuvue Moist
Description: Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
Study: NCT04102007

Intervention type: DRUG
Group type: OTHER
Intervention: Risankizumab
Description: Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).
Study: NCT03861182

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological functionalization of the prosthetic materials by PRF
Description: The biological functionalization of the prosthetic materials by host PRF would improve the biological colonization of materials and thus reduce the risk of prosthetic release.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological functionalization of the prosthetic materials by PRF
Description: The biological functionalization of the prosthetic materials by host PRF would improve the biological colonization of materials and thus reduce the risk of prosthetic release.
Study: NCT00733486

Intervention type: DEVICE
Group type: OTHER
Intervention: L.C.S. APG Knee Anterior Posterior Glide knee
Description: Orthopaedic implant for primary knee replacement
Study: NCT00818090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel and cisplatin
Description: paclitaxel and cisplatin every 3 weeks
Study: NCT03895190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flourishing App Program
Description: This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
Study: NCT00251836

Intervention type: PROCEDURE
Intervention: Laparoscopic hand-assisted donor nephrectomy

Intervention type: PROCEDURE
Intervention: Laparoscopic hand-assisted donor nephrectomy
Study: NCT01248793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab 50 mg SC injection every 4 weeks for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab (placebo group)
Description: Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
Study: NCT05017870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSR-001
Description: (0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
Study: NCT00773370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APA-Stroke
Description: Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sittercise
Description: Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
Study: NCT00767754

Intervention type: DRUG
Group type: OTHER
Intervention: Paxil CR
Description: 12 week treatment of Paxil(20-40mg)
Study: NCT01123408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: 500 mg/day
Study: NCT01621724

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WT1 TCR-transduced T cells
Description: Two patient cohorts:~Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells~Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells
Study: NCT04248790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile app to improve adherence to PrEP self-management
Description: Access to the mobile app which includes the sex and PrEP diary, information on HIV/STI testing, PrEP reminders and geo-location features.
Study: NCT01206452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ablation Procedure
Description: Atrial Fibrillation (AF) ablation
Study: NCT01123408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 20 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 20 mg/day
Study: NCT01206452

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation Procedure
Description: Atrial Fibrillation (AF) ablation
Study: NCT01807195

Intervention type: OTHER
Intervention: contrast medium usage
Study: NCT02627469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended professional oral hygiene care
Description: Weekly professional oral hygiene performed by dental hygienists

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Oral-B Professional Care 7000)
Description: Weekly professional oral hygiene performed by dental hygienists

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1100 ppm sodium fluoride dentifrice (Zendium Classic)
Description: Weekly professional oral hygiene performed by dental hygienists
Study: NCT05017870

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KSR-004
Description: (0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSR-001-02
Description: KSR-001-02
Study: NCT00538122

Intervention type: DEVICE
Intervention: 24 Holter Monitor Recording
Description: All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.~From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects.
Study: NCT03573518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX 1503
Description: BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX 1503
Description: BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX 1503
Description: BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo
Study: NCT00929760

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: specialised renal care
Description: * Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.~* Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: specialised renal care
Description: * Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.~* Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG.
Study: NCT01263613

Intervention type: PROCEDURE
Group type: OTHER
Intervention: tumor biopsy and blood draw
Description: tumor biopsy and blood draw during and after chemotherapy
Study: NCT04425551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser light
Description: laser light destruction of telangiectatic vessels of lower eyelid margin via selective thermolysis
Study: NCT02612844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0143-0406
Description: Subject will receive one single dose only Subcutanesously (s.c., under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Subject will receive one single dose only. Subcutanesously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
Study: NCT04336059

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pericapsular nerve group block
Description: The regional block will be performed with the patient in the supine position under complete sterile technique. A low frequency curvilinear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliacspine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminance(IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will observed.~A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly after local infiltration of the site of the block with 3 ml lidocaine 2%. Following negative aspiration,the normal saline solution will injected in 5-mL increments while observing for adequate fluid spread in this plane.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pericapsular nerve group block
Description: The regional block will be performed with the patient in the supine position under complete sterile technique. A low frequency curvilinear ultrasound probe will be initially placed in a transverse plane over the anterior inferior iliacspine (AIIS) and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminance(IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will observed.~A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly after local infiltration of the site of the block with 3 ml lidocaine 2%. Following negative aspiration,the normal saline solution will injected in 5-mL increments while observing for adequate fluid spread in this plane.